Cargando…
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
Autores principales: | Spanjaart, A. M., Pennings, E., Mutsaers, P., van Dorp, S., Jak, M., van Doesem, J., de Boer, J., Vermaat, J., Sijs-Szabo, A., van der Poel, M., Kuipers, I., Chamuleau, M., Nijhof, I., Minnema, M., Lugtenburg, P., van Meerten, T., Kersten, M. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429214/ http://dx.doi.org/10.1097/01.HS9.0000848704.84354.44 |
Ejemplares similares
-
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
por: Spanjaart, Anne M., et al.
Publicado: (2023) -
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
por: de Boer, Janneke W., et al.
Publicado: (2023) -
P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY
por: Pennings, Elise R.A., et al.
Publicado: (2023) -
Inflammatory reactions mimic residual or recurrent lymphoma on [(18)F]FDG-PET/CT after CD19-directed CAR T-cell therapy
por: de Boer, Janneke W., et al.
Publicado: (2023) -
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
por: Spanjaart, Anne M., et al.
Publicado: (2023)